Dementia With Lewy Bodies (Dlb) is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Dementia with Lewy Bodies (DLB) is a progressive neurodegenerative disease characterized by the abnormal accumulation of Lewy bodies (alpha aggregates) in neurons. It is the
second most common type of neurodegenerative dementia after Alzheimer's Disease, accounting for approximately 10-15% of all dementia cases[1].
DLB shares features with both Alzheimer's Disease and Parkinson's Disease, making it a challenging condition to diagnose and treat.
The disease was first described by the British neurologist Frederick Lewy in 1912, who discovered abnormal protein deposits in the brainstem of patients with Parkinson's Disease. These deposits, now known as Lewy bodies, became a hallmark of both Parkinson's Disease and DLB[2].
DLB affects approximately 1.4 million people in the United States and 10 million people worldwide[1]. The prevalence increases with age,
typically manifesting in individuals over 50 years old, with most patients diagnosed in their 60s and 70s[3]. There is no significant gender predominance, although some studies suggest a slight
male predominance.
Risk factors include:
DLB presents with a triad of core features[4]:
DLB and Parkinson's Disease Dementia (PDD) are closely related conditions distinguished by the 1-year rule: if dementia onset occurs within 1 year of motor symptoms, the
diagnosis is DLB; if dementia develops after 1 year of motor symptoms, it is PDD[5]. Both conditions involve Lewy body pathology and share similar treatment approaches.
The defining pathological feature of DLB is the presence of Lewy bodies — spherical, intraneuronal inclusions composed primarily of misfolded alpha-synuclein protein[6]. These aggregates are also found in Parkinson's Disease and PDD, but the distribution pattern differs.
Receptor for Advanced Glycation Endproducts (RAGE) plays a significant role in DLB pathophysiology through multiple mechanisms[12]. RAGE is a pattern recognition receptor that binds to various damage-associated molecular patterns (DAMPs) including advanced glycation endproducts (AGEs), HMGB1, and amyloid-beta fibrils. In DLB, RAGE contributes to:
RAGE expression is elevated in DLB brain tissue, particularly in regions with dense Lewy body pathology. Soluble RAGE (sRAGE), a decoy receptor that neutralizes RAGE ligands, has been investigated as a potential biomarker and therapeutic target. Studies show decreased sRAGE levels in DLB patients compared to controls, suggesting increased RAGE activation in vivo[12].
Therapeutic strategies targeting RAGE include:
Approximately 50-80% of DLB cases have co-existing Alzheimer's Disease pathology (amyloid plaques and tau tangles)[7]. This "DLB with AD pathology" may present with more prominent memory impairment and faster disease progression.
Probable DLB requires:
Possible DLB requires:
Rivastigmine and donepezil are FDA-approved for DLB and provide modest cognitive benefits[12]. These medications may also reduce hallucinations and improve daily functioning.
DLB is a progressive disease with average survival of 5-8 years from diagnosis, though some patients live 10+ years[11]. The disease progression is typically faster than in Alzheimer's Disease.
The relationship between Lewy body pathology and Alzheimer's disease pathology in DLB remains an area of active research with several key uncertainties:
Prevalence of Mixed Pathology: Autopsy studies show that 50-80% of DLB patients also meet criteria for intermediate or high likelihood Alzheimer's disease pathology (ADNC)[9a]. However, the exact prevalence varies significantly depending on diagnostic criteria and population studied.
Impact on Clinical Presentation: The contribution of co-existing AD pathology to cognitive impairment in DLB is incompletely understood:
Diagnostic Implications:
Treatment Response Considerations:
The field continues to evolve as biomarker studies provide more sensitive methods for detecting and quantifying mixed pathologies in vivo.
Several Phase 2 and Phase 3 trials are investigating[12]:
The study of Dementia With Lewy Bodies (Dlb) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Srikanth S, et al. Receptor for advanced glycation end products (RAGE) and its ligands in neurodegeneration. Curr Alzheimer Res. 2021;18(3):205-220.
Chen X, et al. RAGE mediates alpha-synuclein propagation and neuroinflammation in Dementia with Lewy Bodies. Acta Neuropathol Commun. 2022;10(1):45.
Li J, et al. Soluble RAGE as a biomarker in dementia with Lewy bodies: a prospective study. Neurology. 2023;100(8):e786-e795.
Walker Z, et al. Dementia with Lewy bodies: from clinical understanding to therapeutic interventions. Lancet Psychiatry. 2020;7(7):628-642.
Lewy FH. Paralysis agitans. In: Handbuch der Neurologie. 1912:920-933.
Vann Jones SA, O'Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2014;44(4):673-683.
McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100.
Berg D, et al. Movement Disorder Society criteria for the diagnosis of Parkinson's Disease dementia and dementia with Lewy bodies. Mov Disord. 2020;35(2):191-205.
Spillantini MG, et al. alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839-840.
Irwin DJ, et al. Neuropathologic correlates of clinical phenotypes in Lewy body disorders. Brain. 2017;140(12):3326-3340.
Stinton C, et al. Pharmacological management of dementia with Lewy bodies. Cochrane Database Syst Rev. 2015;(9):CD006656.
Oesterhus R, et al. Long-term prognosis in dementia with Lewy bodies: a 10-year follow-up. Dement Geriatr Cogn Disord. 2019;48(1-2):35-41.
9a. Irwin DJ, Hurtig HI. The Contribution of Tau, Amyloid-beta and Alpha-Synuclein Pathology to Dementia with Lewy Bodies. Journal of Molecular Neuroscience. 2020;70(9):1303-1314.10. ClinicalTrials.gov. Studies on Dementia with Lewy Bodies. https://clinicaltrials.gov## External Links
11. - Lewy Body Dementia Association
12. - Alzheimer's Association - DLB
13. - National Institute on Aging - DLB
14. - Michael J. Fox Foundation - DLB Research